Astrana Health, Inc. (ASTH) P/E Ratio History
ExpensiveTrading at 86.1x vs 5Y avg 41.4x · 94th percentile · Material premium to history · Data 2022–2026
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Astrana Health, Inc. (ASTH) trades at a price-to-earnings ratio of 86.1x, with a stock price of $39.59 and trailing twelve-month earnings per share of $0.62.
The current P/E is 108% above its 5-year average of 41.4x. Over the past five years, ASTH's P/E has ranged from a low of 24.1x to a high of 143.5x, placing the current valuation at the 94th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ASTH trades at a 289% premium to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, ASTH commands a significant premium over the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ASTH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ASTH Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ASTH P/E vs Peers
Physician platforms and value-based care peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $148B | 152.1 | - | -11% | |
| $4B | 20.5 | 0.40Best | -12% | |
| $3B | 130.5 | - | +64% | |
| $369B | 30.7 | - | -15% | |
| $129B | 72.9 | - | -62% | |
| $74B | 12.7Lowest | - | +83%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ASTH Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $24.52 | $0.61 | 40.4x | -2% |
| FY2025 Q4 | Dec 31 2025 | $24.81 | $0.46 | 54.2x | +31% |
| FY2025 Q3 | - | $28.35 | $0.20 | 143.5x | +247% |
| FY2025 Q2 | Jun 30 2025 | $24.88 | $0.52 | 47.8x | +16% |
| FY2025 Q1 | Mar 31 2025 | $31.01 | $0.73 | 42.5x | +3% |
| FY2024 Q4 | - | $31.53 | $0.90 | 35.0x | -15% |
| FY2024 Q3 | Sep 30 2024 | $57.94 | $1.30 | 44.6x | +8% |
| FY2024 Q2 | Jun 30 2024 | $40.56 | $1.44 | 28.2x | -32% |
| FY2024 Q1 | Mar 31 2024 | $41.99 | $1.32 | 31.8x | -23% |
| FY2023 Q4 | Dec 31 2023 | $38.30 | $1.29 | 29.7x | -28% |
| FY2023 Q3 | Sep 30 2023 | $30.85 | $0.97 | 31.7x | -23% |
| FY2023 Q2 | Jun 30 2023 | $31.60 | $1.06 | 29.7x | -28% |
| FY2023 Q1 | Mar 31 2023 | $36.47 | $1.03 | 35.3x | -15% |
| FY2022 Q4 | Dec 31 2022 | $29.59 | $1.06 | 27.8x | -33% |
| FY2022 Q3 | Sep 30 2022 | $39.00 | $1.42 | 27.5x | -34% |
| FY2022 Q2 | - | $38.59 | $1.60 | 24.1x | -42% |
| FY2022 Q1 | - | $48.47 | $1.63 | 29.7x | -28% |
Average P/E for displayed period: 41.4x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ASTH — Frequently Asked Questions
Quick answers to the most common questions about buying ASTH stock.
What is ASTH's P/E ratio?
Astrana Health, Inc. (ASTH) trailing twelve-month P/E ratio is 86.1x, based on TTM diluted EPS of $0.62. The 5-year average P/E is 41.4x and the historical range spans 24.1x to 143.5x.
Is ASTH stock overvalued or undervalued?
ASTH trades at 86.1x P/E, above its 5-year average of 41.4x. The 94th percentile ranking within the 24.1x–143.5x historical range indicates a premium to historical valuation.
Is ASTH stock expensive?
Yes, ASTH is expensive relative to its own history. The current P/E of 86.1x is above the 5-year average of 41.4x and also above the Healthcare sector median of 22.1x. The stock sits at the 94th percentile of its 5-year valuation range.
What is ASTH's historical P/E range?
Over the past 5 years, ASTH's P/E ratio has ranged from 24.1x to 143.5x, with a median of 31.8x and an average of 41.4x. The current P/E of 86.1x places the stock at the 94th percentile of this range. Full historical data spans 2022–2026.
How does ASTH's P/E compare to the S&P 500?
ASTH trades at 86.1x P/E versus the S&P 500 median of 24.3x. The 254% premium to the market typically reflects higher expected earnings growth or quality.
How does ASTH's valuation compare to Healthcare peers?
Astrana Health, Inc. P/E of 86.1x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ASTH's PEG ratio?
ASTH PEG ratio is N/A, based on a P/E of 86.1x and EPS growth of -48.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ASTH's earnings yield?
ASTH earnings yield is 1.16%, the inverse of its 86.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.